GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » Cyclically Adjusted PS Ratio

NVZMF (Novonesis (Novozymes) B) Cyclically Adjusted PS Ratio : 7.20 (As of May. 15, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Cyclically Adjusted PS Ratio?

As of today (2025-05-15), Novonesis (Novozymes) B's current share price is $65.63. Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $9.12. Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio for today is 7.20.

The historical rank and industry rank for Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio or its related term are showing as below:

NVZMF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.01   Med: 7.68   Max: 11.43
Current: 6.98

During the past years, Novonesis (Novozymes) B's highest Cyclically Adjusted PS Ratio was 11.43. The lowest was 5.01. And the median was 7.68.

NVZMF's Cyclically Adjusted PS Ratio is ranked worse than
91.4% of 1163 companies
in the Chemicals industry
Industry Median: 1.25 vs NVZMF: 6.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted revenue per share data for the three months ended in Mar. 2025 was $2.489. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $9.12 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.82 11.24 6.49 6.37 6.57

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.37 6.82 7.13 6.57 6.34

Competitive Comparison of Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio falls into.


;
;

Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=65.63/9.12
=7.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novonesis (Novozymes) B's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.489/120.2000*120.2000
=2.489

Current CPI (Mar. 2025) = 120.2000.

Novonesis (Novozymes) B Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 1.667 100.200 2.000
201506 1.671 100.300 2.003
201509 1.715 100.200 2.057
201512 1.637 99.800 1.972
201603 1.762 100.200 2.114
201606 1.701 100.600 2.032
201609 1.688 100.200 2.025
201612 1.774 100.300 2.126
201703 1.798 101.200 2.136
201706 1.794 101.200 2.131
201709 1.941 101.800 2.292
201712 1.956 101.300 2.321
201803 1.974 101.700 2.333
201806 1.871 102.300 2.198
201809 1.958 102.400 2.298
201812 1.953 102.100 2.299
201903 1.823 102.900 2.129
201906 1.817 102.900 2.122
201909 1.912 102.900 2.233
201912 1.954 102.900 2.283
202003 1.977 103.300 2.300
202006 1.791 103.200 2.086
202009 1.929 103.500 2.240
202012 2.009 103.400 2.335
202103 2.152 104.300 2.480
202106 2.066 105.000 2.365
202109 2.127 105.800 2.416
202112 2.080 106.600 2.345
202203 2.316 109.900 2.533
202206 2.179 113.600 2.306
202209 2.088 116.400 2.156
202212 2.304 115.900 2.389
202303 2.392 117.300 2.451
202306 2.208 116.400 2.280
202309 2.291 117.400 2.346
202312 4.773 116.700 4.916
202403 2.132 118.400 2.164
202406 2.120 118.500 2.150
202412 4.593 118.900 4.643
202503 2.489 120.200 2.489

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novonesis (Novozymes) B  (OTCPK:NVZMF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q3 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024